Hematology Diagnostics Market Demand, Size, Report to 2032
The global hematology diagnostics market size was exhibited at USD 19.2 billion in 2022 and is projected to hit around USD 33.93 billion by 2032, growing at a CAGR of 5.86% during the forecast period 2023 to 2032.
Key Pointers:
Hematology Diagnostics Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 20.33 Billion |
| Market Size by 2032 | USD 33.93 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 5.86% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product, Test type, End-use |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Beckman Coulter, Inc.; Siemens Healthineers; Mindray Medical International Limited; F. Hoffmann-La Roche Ltd.; Sysmex Corporation |
The factors such as increasing prevalence of blood disorders coupled with increasing awareness about these disorders, and the presence of sophisticated & advanced technologies are anticipated to propel the market growth.
According to an article published by Bristol-Myers Squibb, nearly 1 million new cases of blood cancer are expected to be diagnosed by 2020, which is anticipated to account for nearly 7.0% of all new cancer. Furthermore, a significant number of the world population have different hemoglobinopathies. High prevalence of blood disorders, such as thalassemia is anticipated to boost the demand for hematology testing.
Increasing prevalence of blood disorders coupled with adoption of automated testing processes are projected to propel the market growth.
Automation of hematology diagnostics process have led to reduced turnaround time thereby accelerating the overall treatment regimen. Furthermore, automation has also led to reduced administrative errors and overall costs of diagnostic tests. Thus, it is expected to boost growth of the hematology testing market in the forthcoming years.
Dominance of hematology analyzers can be attributed to the presence of fully-automated analyzers which are objective, have high-throughput, and are cost-effective. Furthermore, these hematology analyzers can also detect atypical results and can improve measurable parameters such as red cell distribution width, platelet distribution, Reticulocyte (RET) counts, and nucleated red cells counts.
The advent of Point-Of-Care (PoC) hematology testing devices has led to improved diagnostic and patient outcomes. These devices are user-friendly and are available for use outside the hospital settings. This is anticipated to increase the acceptability and accessibility of hematology testing which, in turn, is anticipated to propel market growth.
Product recall and intense market competition leading to price wars are anticipated to hinder market growth. In 2022, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes owing to chemical interference with certain tests. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA), thereby indicating that the use of these devices may cause serious injuries or death. Such product recalls can negatively affect the market growth.
Some of the prominent players in the Hematology Diagnostics Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Hematology Diagnostics market.
By Product
By End-use
By Test Type
By Region
Chapter 1 Research Test typology
1.1 Information procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.2 Growing incidence of chronic conditions
3.1.1.3 Technological advancement
3.1.1.4 Increasing awareness of blood disorders
3.1.2 Market Restraint Analysis
3.1.2.1 Product recalls
3.1.2.2 High cost of products
3.2 Penetration & growth prospect mapping
3.3 Hematology Testing market - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
Chapter 4 Product Estimates & Trend Analysis
4.1 Hematology Testing market: Product movement analysis
4.2 Instruments
4.2.1 Hematology instruments market, 2020 - 2032
4.3 Consumables
4.3.1 Hematology consumables market, 2020 - 2032
Chapter 5 Test Type Estimates & Trend Analysis
5.1 Hematology Testing market: Test movement analysis
5.2 Blood count
5.2.1 Blood count market, 2020 - 2032
5.3 Platelet function
5.3.1 Platelet function testing market, 2020 - 2032
5.4 Hemoglobin
5.4.1 Hemoglobin market, 2020 - 2032
5.5 Hematocrit
5.5.1 Hematocrit market, 2020 - 2032
Chapter 6 End-use Estimates & Trend Analysis
6.1 Hematology Testing market: End-use movement analysis
6.2 Hospitals
6.2.1 Hospitals market, 2020 - 2032
6.3 Diagnostic labs
6.3.1 Diagnostic labs market, 2020 - 2032
6.4 Others
6.4.1 Others market, 2020 - 2032
Chapter 8 Regional Estimates & Trend Analysis
8.1 Hematology Testing market share by region, 2017 & 2032
8.2 North America
8.2.1 North America Hematology Testing market, 2020 - 2032
8.2.2 U.S.
8.2.2.1 U.S. Hematology Testing market, 2020 - 2032
8.2.3 Canada
8.2.3.1 Canada Hematology Testing market, 2020 - 2032
8.3 Europe
8.3.1 Europe Hematology Testing market, 2020 - 2032
8.3.2 U.K.
8.3.2.1 U.K. Hematology Testing market, 2020 - 2032
8.3.3 Germany
8.3.3.1 Germany Hematology Testing market, 2020 - 2032
8.4 Asia Pacific
8.4.1 Asia Pacific Hematology Testing market, 2020 - 2032
8.4.2 Japan
8.4.2.1 Japan Hematology Testing market, 2020 - 2032
8.4.3 China
8.4.3.1 China Hematology Testing market, 2020 - 2032
8.5 Latin America
8.5.1 Latin America Hematology Testing market, 2020 - 2032
8.5.2 Brazil
8.5.2.1 Brazil Hematology Testing market, 2020 - 2032
8.5.3 Mexico
8.5.3.1 Mexico Hematology Testing market, 2020 - 2032
8.6 MEA
8.6.1 MEA Hematology Testing market, 2020 - 2032
8.6.2 South Africa
8.6.2.1 South Africa Hematology Testing market, 2020 - 2032
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia Hematology Testing market, 2020 - 2032
Chapter 9 Competitive Landscape
9.1 Strategy framework
9.2 Company Profiles
9.2.1 Abbott
9.2.1.1 Company Overview
9.2.1.2 Financial Performance
9.2.1.3 Product Benchmarking
9.2.1.4 Strategic Initiatives
9.2.2 Beckman Coulter
9.2.2.1 Company Overview
9.2.2.2 Financial Performance
9.2.2.3 Product Benchmarking
9.2.2.4 Strategic Initiatives
9.2.3 Sysmex Corporation
9.2.3.1 Company Overview
9.2.3.2 Financial Performance
9.2.3.3 Product Benchmarking
9.2.4 Horiba
9.2.4.1 Company Overview
9.2.4.2 Financial Performance
9.2.4.3 Product Benchmarking
9.2.4.4 Strategic Initiatives
9.2.5 Bio-Rad Laboratories
9.2.5.1 Company Overview
9.2.5.2 Financial Performance
9.2.5.3 Product Benchmarking
9.2.5.4 Strategic Initiatives
9.2.6 Siemens Healthcare
9.2.6.1 Company Overview
9.2.6.2 Financial Performance
9.2.6.3 Product Benchmarking
9.2.7 F. Hoffmann-La Roche Ltd
9.2.7.1 Company Overview
9.2.7.2 Financial Performance
9.2.7.3 Product Benchmarking
9.2.7.4 Strategic Initiatives
9.2.8 Mindray
9.2.8.1 Company Overview
9.2.8.2 Financial Performance
9.2.8.3 Product Benchmarking
9.2.8.4 Strategic Initiatives
9.2.9 Nihon Kohden
9.2.9.1 Company Overview
9.2.9.2 Financial Performance
9.2.9.3 Product Benchmarking
9.2.10 EKF Diagnostics
9.2.10.1 Company Overview
9.2.10.2 Financial Performance
9.2.10.3 Product Benchmarking
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers